Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TAK 
Takeda Pharmaceutical Co Ltd ADR (TAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: TAK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.36
1 Year Target Price $18.36
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.6% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 48.19B USD | Price to earnings Ratio 51.93 | 1Y Target Price 18.36 |
Price to earnings Ratio 51.93 | 1Y Target Price 18.36 | ||
Volume (30-day avg) 4 | Beta 0.27 | 52 Weeks Range 12.51 - 15.69 | Updated Date 09/15/2025 |
52 Weeks Range 12.51 - 15.69 | Updated Date 09/15/2025 | ||
Dividends yield (FY) 4.40% | Basic EPS (TTM) 0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.06% | Operating Margin (TTM) 16.89% |
Management Effectiveness
Return on Assets (TTM) 2.31% | Return on Equity (TTM) 1.87% |
Valuation
Trailing PE 51.93 | Forward PE 14.84 | Enterprise Value 75948758000 | Price to Sales(TTM) 0.01 |
Enterprise Value 75948758000 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 9.94 | Shares Outstanding 3158220032 | Shares Floating 1561025417 |
Shares Outstanding 3158220032 | Shares Floating 1561025417 | ||
Percent Insiders 0.01 | Percent Institutions 2.51 |
Upturn AI SWOT
Takeda Pharmaceutical Co Ltd ADR
Company Overview
History and Background
Takeda Pharmaceutical Company Limited was founded in 1781 in Osaka, Japan. Initially a medicine wholesaler, it evolved into a global pharmaceutical company through organic growth and strategic acquisitions.
Core Business Areas
- Gastroenterology: Focuses on treatments for gastrointestinal disorders such as inflammatory bowel disease (IBD) and short bowel syndrome (SBS).
- Rare Diseases: Develops and markets therapies for rare genetic and hematologic diseases.
- Plasma-Derived Therapies: Offers plasma-derived products for immune deficiencies, bleeding disorders, and other conditions.
- Oncology: Develops therapies for various types of cancer, including hematologic malignancies and solid tumors.
- Neuroscience: Focuses on treatments for neurological and psychiatric disorders, such as ADHD and depression.
Leadership and Structure
Takeda is led by Christophe Weber (CEO). The organizational structure includes global business units and regional operations.
Top Products and Market Share
Key Offerings
- Entyvio: An integrin receptor antagonist used to treat ulcerative colitis and Crohn's disease. Competitors include: Stelara (JNJ), Humira (ABBV), Remicade (JNJ). 2023 Revenue: ~ $5 Billion. Market share is estimated at around 20% of the IBD biologics market.
- Vyvanse/Elvanse: A central nervous system stimulant used to treat ADHD and binge eating disorder (marketed as Elvanse outside of the US). Competitors: Adderall (multiple generics), Concerta (JNJ). 2023 revenue ~$2.5 Billion. The market share is estimated at around 15% in the ADHD market.
- Livtencity: An antiviral drug approved for post-transplant cytomegalovirus (CMV) infection. Competitors: Letermovir (Merck), Ganciclovir (multiple generics). 2023 revenue ~$200 Million. Estimated to grow to be a blockbuster drug. Market share is estimated around 40% in treating drug resistant CMV infections.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and increasing pressure on pricing.
Positioning
Takeda is a global, research-driven pharmaceutical company with a focus on innovative medicines. It competes with large multinational corporations and smaller biotech firms.
Total Addressable Market (TAM)
The global pharmaceutical market is valued at over $1.4 trillion and is expected to continue to grow. Takeda is well positioned to capitalize on this growth through its diverse portfolio and focus on innovation.
Upturn SWOT Analysis
Strengths
- Global Presence
- Diversified Portfolio
- Strong R&D Capabilities
- Established Brands
- Experienced Management Team
Weaknesses
- High Debt Levels (related to Shire acquisition)
- Patent Expiry Risks
- Dependence on Key Products
- Integration Challenges (Shire acquisition)
- Generic Competition
Opportunities
- Expansion into Emerging Markets
- Development of New Therapies
- Strategic Acquisitions
- Collaboration with Biotech Firms
- Growth in Personalized Medicine
Threats
- Increased Competition
- Pricing Pressures
- Regulatory Changes
- Economic Downturns
- Patent Challenges
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- ABBV
- NVS
Competitive Landscape
Takeda faces intense competition from larger pharmaceutical companies. It differentiates itself through its focus on specific therapeutic areas and its global presence.
Major Acquisitions
Shire
- Year: 2019
- Acquisition Price (USD millions): 62000
- Strategic Rationale: Expanded Takeda's portfolio in rare diseases and strengthened its global presence.
Nimbus Lakshmi, Inc
- Year: 2023
- Acquisition Price (USD millions): 4000
- Strategic Rationale: Acquiring Nimbus Lakshmi reinforces Takedau2019s commitment to GI and creates an exciting opportunity to potentially bring best-in-class targeted therapies to patients living with Crohnu2019s disease.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by key products and strategic acquisitions, particularly the acquisition of Shire.
Future Projections: Analysts expect continued growth, driven by new product launches and expansion into emerging markets.
Recent Initiatives: Recent initiatives include focusing on core therapeutic areas, divesting non-core assets, and investing in R&D.
Summary
Takeda is a global pharmaceutical company with a strong presence in key therapeutic areas, driven by innovative medicines and strategic acquisitions. While the Shire acquisition increased its debt, it also expanded its portfolio. Takeda needs to manage its debt, navigate generic competition, and capitalize on opportunities in emerging markets and personalized medicine. Takeda's success depends on continued investment in research and development and strategic execution.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports (e.g., Reuters, Bloomberg)
- Company Website
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Takeda Pharmaceutical Co Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2008-10-27 | President, CEO & Representative Director Mr. Christophe Weber | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 47455 | Website https://www.takeda.com |
Full time employees 47455 | Website https://www.takeda.com | ||
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.